Although it contains an inactive kinase domain, making it an impractical target for signal inhibition (19,20), the increased density of HER3 on the surfaces of resistant tumor cells provides a useful biomarker for active targeting of those cells and a potentially valuable portal for the accumulation of ErbB-directed therapeutic-loaded nanocarriers. The gene discussed is ERBB3; the disease is neoplasm.